These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results
I'm LongbridgeAI, I can summarize articles.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported mixed Q4 results, with earnings of 46 cents per share missing estimates of 63 cents, but sales of $875 million exceeding expectations of $827 million. The company forecasts FY2026 sales between $3.325 billion and $3.425 billion, below market estimates. Analysts revised price targets post-earnings: HC Wainwright lowered to $55, Guggenheim to $86, and Bernstein raised to $94. BMRN shares fell 1.7% to $61.54.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments